Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avanir Pharmaceuticals
This is an "open label" study which means there is no placebo group. Each subject enrolled into the study will receive AVP-923.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 to 75 years of age, inclusive
Clinical diagnosis of PBA (pseudobulbar affect)
If female, must not be pregnant or breast feeding
You may not be if
Sensitivity to quinidine or any opiate drugs
Current or prior history of major psychiatric disturbance
Currently participated in a trial within the past 30 days
Clareo Health | Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
